NBY
Income statement / Annual
Last year (2023), NovaBay Pharmaceuticals, Inc.'s total revenue was $14.73 M,
an increase of 2.24% from the previous year.
In 2023, NovaBay Pharmaceuticals, Inc.'s net income was -$9.64 M.
See NovaBay Pharmaceuticals, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$14.73 M
|
$14.40 M
|
$8.42 M
|
$9.93 M
|
$6.60 M
|
$12.51 M
|
$18.23 M
|
$11.90 M
|
$4.38 M
|
$1.05 M
|
| Cost of Revenue |
$6.83 M |
$6.62 M |
$2.78 M |
$3.97 M |
$1.74 M |
$1.50 M |
$2.78 M |
$2.46 M |
$1.26 M |
$486,000.00 |
| Gross Profit |
$7.90 M |
$7.78 M |
$5.65 M |
$5.96 M |
$4.86 M |
$11.01 M |
$15.45 M |
$9.43 M |
$3.12 M |
$568,000.00 |
| Gross Profit Ratio |
0.54 |
0.54 |
0.67 |
0.6 |
0.74 |
0.88 |
0.85 |
0.79 |
0.71 |
0.54 |
| Research and Development
Expenses |
$68,000.00
|
$174,000.00
|
$44,000.00
|
$285,000.00
|
$184,000.00
|
$259,000.00
|
$410,000.00
|
$1.37 M
|
$6.05 M
|
$9.51 M
|
| General & Administrative
Expenses |
$6.33 M
|
$7.49 M
|
$7.24 M
|
$5.93 M
|
$5.31 M
|
$5.83 M
|
$8.64 M
|
$7.24 M
|
$18.09 M
|
$7.94 M
|
| Selling & Marketing
Expenses |
$6.50 M
|
$7.80 M
|
$7.22 M
|
$6.17 M
|
$8.77 M
|
$12.79 M
|
$13.71 M
|
$11.81 M
|
$10.52 M
|
$1.75 M
|
| Selling, General &
Administrative Expenses |
$12.83 M
|
$15.29 M
|
$14.46 M
|
$12.11 M
|
$14.08 M
|
$18.62 M
|
$22.35 M
|
$19.04 M
|
$18.09 M
|
$7.94 M
|
| Other Expenses |
-$2.06 M |
-$276,000.00 |
-$1.58 M |
$605,000.00 |
-$1.43 M |
$19,000.00 |
$12,000.00 |
-$68,000.00 |
-$96,000.00 |
$22,000.00 |
| Operating Expenses |
$12.90 M |
$15.46 M |
$14.51 M |
$12.39 M |
$14.26 M |
$18.88 M |
$22.76 M |
$20.42 M |
$24.13 M |
$17.45 M |
| Cost And Expenses |
$19.73 M |
$22.08 M |
$17.28 M |
$16.36 M |
$16.00 M |
$20.38 M |
$25.54 M |
$22.88 M |
$25.40 M |
$17.93 M |
| Interest Income |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$0.00 |
-$3.81 M |
$0.00 |
-$129,179.00 |
$1.05 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$203,000.00
|
$483,000.00
|
$119,000.00
|
$51,000.00
|
$65,000.00
|
$266,000.00
|
$95,000.00
|
$114,000.00
|
$164,000.00
|
$232,000.00
|
| EBITDA |
-$4.80 M
|
-$4.55 M
|
-$13.36 M
|
-$1.16 M
|
-$10.51 M
|
-$8.92 M
|
-$7.12 M
|
-$8.77 M
|
-$23.00 M
|
-$18.31 M
|
| EBITDA Ratio |
-0.33 |
-0.32 |
-1.59 |
-0.12 |
-1.59 |
-0.71 |
-0.39 |
-0.74 |
-5.25 |
-17.37 |
| Operating Income Ratio
|
-0.34
|
-0.53
|
-1.05
|
-0.65
|
-1.42
|
-0.63
|
-0.4
|
-0.92
|
-4.8
|
-16.01
|
| Total Other
Income/Expenses Net |
-$4.64 M
|
-$2.93 M
|
$3.04 M
|
-$4.61 M
|
-$252,000.00
|
$1.33 M
|
-$89,000.00
|
-$2.17 M
|
$2.17 M
|
$1.71 M
|
| Income Before Tax |
-$9.64 M |
-$10.61 M |
-$5.82 M |
-$11.03 M |
-$9.65 M |
-$6.54 M |
-$7.40 M |
-$13.15 M |
-$18.97 M |
-$15.19 M |
| Income Before Tax Ratio
|
-0.65
|
-0.74
|
-0.69
|
-1.11
|
-1.46
|
-0.52
|
-0.41
|
-1.11
|
-4.33
|
-14.41
|
| Income Tax Expense |
$35,105.00 |
-$3.81 M |
-$4.62 M |
$5,000.00 |
$6,000.00 |
$4,000.00 |
$3,000.00 |
$2,000.00 |
$12,000.00 |
$2,000.00 |
| Net Income |
-$9.64 M |
-$16.27 M |
-$6.56 M |
-$11.04 M |
-$10.49 M |
-$6.55 M |
-$7.40 M |
-$13.15 M |
-$18.97 M |
-$15.19 M |
| Net Income Ratio |
-0.65 |
-1.13 |
-0.78 |
-1.11 |
-1.59 |
-0.52 |
-0.41 |
-1.11 |
-4.33 |
-14.42 |
| EPS |
-2.29 |
-10.1 |
-5.26 |
-11.02 |
-16.96 |
-13.54 |
-16.91 |
-49 |
-238.7 |
-267.91 |
| EPS Diluted |
-2.29 |
-10.1 |
-5.26 |
-11.02 |
-16.96 |
-13.43 |
-16.91 |
-48.92 |
-238.53 |
-267.91 |
| Weighted Average Shares
Out |
$4.22 M
|
$1.61 M
|
$1.25 M
|
$1.00 M
|
$618,314.00
|
$483,457.00
|
$437,828.00
|
$268,387.00
|
$79,484.00
|
$56,714.00
|
| Weighted Average Shares
Out Diluted |
$4.22 M
|
$1.61 M
|
$1.25 M
|
$1.00 M
|
$618,314.00
|
$487,371.00
|
$437,828.00
|
$268,800.00
|
$79,542.00
|
$56,714.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
